Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.
“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the ...
Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic ...
Scientists at Mount Sinai have unveiled a bold new way to fight metastatic cancer by turning the tumor’s own defenses against ...
Hosted on MSN
What Is Metastatic Cancer? How It Spreads, What It Means And Why Chemotherapy Isn’t Always Enough
Many cancers can often be treated successfully when detected early. Surgery, radiation and chemotherapy are all powerful tools to remove or destroy tumors in their original location. However, when ...
A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...
An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...
Takeda Canada Inc. ("Takeda") is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results